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Abstract
Background: The Major Histocompatibility Complex is the main genetic contributor to susceptibility to type 1 diabetes (T1D);
genome-wide scans have consistently mapped increased predisposition to this region. The highest disease risk has been
associated with HLA-DR3 and HLA-DR4. In particular, the DR3-positive ancestral haplotype 18.2 was reported as highly
diabetogenic. We aimed to corroborate whether this haplotype increases the susceptibility conferred by the DQ2-DR3 alleles
in a Mediterranean population. We also searched for additional susceptibility factors to the classic DQ2-DR3 and DQ8-DR4.
Results: Genetic MHC markers were analysed in a case-control study with 302 T1D patients and 529 ethnically matched
controls. DR3-TNFa1b5 carrier rate was significantly higher in DR3-positive heterozygous T1D patients than in DR3-positive
heterozygous controls (p = 0.0019; odds ratio OR [95% confidence interval CI] = 2.26 [1.3–3.93]). This data was confirmed
analysing the allelic frequency, which includes the information corresponding to the DR3-homozygous individuals (p = 0.001;
OR = 2.09) and by using the Arlequin software to check the DR3-positive haplotypes (p = 0.004;OR = 1.93). The present results
provide strong evidence of a second susceptibility region in the ancestral haplotype 18.2 in the Spanish population.
Moreover, we searched for T1D susceptibility factors in addition to the MHC classical ones, within the DR2-DQ6/DR3-DQ2/
DR4-DQ8 negative population. Several genetic markers in both MHC class II (DQA1*0101-DQB1*0501 [p = 0.007;OR = 2.81],
DQA1*0201-DQB1*0202 [p = 0.03; OR = 2.35]) and III (TNFa2b1 [p = 0.01 OR = 2.74], BAT-2*2 [p = 0.004; OR = 3.19]) were
found. These different alleles associated with T1D were not independent and we observed linkage disequilibrium among them
leading us to describe two new risk haplotypes (DQA1*0101-DQB1*0501-TNFa2b1 and DQA1*0201-DQB1*0202- BAT-2*2).
Finally, we studied a T1D susceptibility/protection marker located in extended class I, D6S2223; however, no association was
observed in our population.
Conclusion: Our results suggest that other associated MHC haplotypes might present susceptibility factors in loci different
from HLA-class II and that the class II molecules are not necessarily the universal etiologic factor in every MHC haplotype.
Published: 20 April 2005
BMC Genomics 2005, 6:56 doi:10.1186/1471-2164-6-56
Received: 15 November 2004
Accepted: 20 April 2005
This article is available from: http://www.biomedcentral.com/1471-2164/6/56
© 2005 Urcelay et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Genomics 2005, 6:56 http://www.biomedcentral.com/1471-2164/6/56
Page 2 of 7
(page number not for citation purposes)
Background
Type 1 diabetes is a multifactorial autoimmune disease
characterised by insulin deficiency, due to the T cell medi-
ated destruction of pancreatic β -cells [1]. Among the
genetic determinants of susceptibility, with more than 18
putative loci identified to date, a region in chromosome
6p21 (IDDM1) containing the Major Histocompatibility
Complex (MHC) is the only one consistently associated
with T1D in genome-wide screenings. The MHC spans
approximately 4 Mb and consists of over 200 genes
arranged in three subregions named class II, III and I.
More than 90% of Caucasoid type 1 diabetic patients have
at least one copy of the class II HLA-DR3 or DR4 allele, as
compared to the 45% present in the general population
and the genotype frequency of the DR3/DR4 heterozygote
in T1D patients is 40% vs. 3% in controls [2]. In fact, the
strongest susceptibility haplotypes described are
DQB1*0201-DQA1*0501-DRB1*03 (DQ2-DR3) and
DQB1*0302-DQA1*0301-DRB1*04 (DQ8-DR4), espe-
cially when both appear together in the genotype. How-
ever, not all HLA-DR3 or -DR4 positive haplotypes are
equally predisposing [3,4]. This might suggest the role of
other MHC loci responsible for modifying the susceptibil-
ity to diabetes conferred by class II genes, but their search
has been difficult due to the strong linkage disequilibrium
(LD) present in this chromosomal region. The term ances-
tral, extended haplotype was coined referring to continu-
ous sequence derived with little, if any, change from an
ancestor of all those now carrying all or part of the haplo-
type [5]. A published report stated that the DQ2-DR3-B18
AH 18.2 significantly increased risk compared to other
haplotypes with the same class II alleles, but LD between
markers hampered a more precise localisation of the pre-
sumed susceptibility gene [6]. Taking into account that
this AH 18.2 is more frequent in Southern European pop-
ulations, we decided to assess the possible role of other
loci in the MHC region besides DQ-DR within this haplo-
type. We evaluated several genetic markers along the MHC
in a case-control study with 302 Spanish T1D patients and
529 healthy controls. This study reproduced the especially
strong association of the AH 18.2 with T1D in the Spanish
population, supporting the existence of a second suscepti-
bility locus within this haplotype. The present work
extended the search to other T1D risk factors in the MHC
besides DQ2-DR3/DQ8-DR4. Additional MHC haplo-
types question the paradigm of class II genes as sole
responsible for the association and open up the possibil-
ity that class III susceptibility factors would be also
involved.
Results
We first aimed to corroborate in the Spanish population
the published increased risk to autoimmune diabetes of
the AH 18.2, as compared to other DR3-positive haplo-
types [6]. Microsatellites TNFa and TNFb, located in the
untranslated region upstream of the LTA gene, exhibit
extensive polymorphism and are good haplospecific
markers. In order to identify the extended haplotype AH
18.2, we selected both microsatellites TNFab, which are
conveniently close to HLA-B and easier to genotype than
the latter. The microsatellites TNFa1b5 tag the AH18.2
defined by the characteristic alleles of five markers
(D6S273*2, BAT2*2, TNFa1b5, MICA*4) in our families
with IgA deficiency [7] and celiac disease [8]. These AH
18.2 markers were also confirmed by the computer pro-
gram Arlequin, by linkage disequilibrium studies and by
analysis of homozygous individuals. As we are dealing
with patients and controls with no families at our dis-
posal, the DR3-TNFa1b5 phase was uncertain. However,
due to heavy linkage disequilibrium between these alleles,
most of the times they will probably be in cis. This propor-
tion can be estimated based upon the presence of
TNFa1b5 in DR3-negative individuals: 8 carriers out of
109 DR3-negative T1D patients, and 13 carriers out of 376
DR3-negative healthy controls. These numbers yield
allelic frequencies of TNFa1b5 on DR3-negative haplo-
types of 7 and 3%, respectively. The assumption can there-
fore be made that, most of the time; a DR3 heterozygous
sample carrying TNFa1b5 will in fact carry these alleles in
the same haplotype.
Once the AH 18.2 was defined, we looked for the already
described different distribution of this haplotype between
T1D patient and control cohorts. Initially, we compared
the carrier rate of TNFa1b5 among DR3-positive individ-
uals. In T1D patients, the ratio of DR3 homozygous sub-
jects out of the total DR3-positive individuals is much
higher than the observed in controls (47 out of 193 vs. 8
out of 153 in controls; p = 1 × 10-6; OR = 5.83). This
makes necessary to calculate the TNFa1b5 carrier rate
exclusively in DR3 heterozygous individuals to avoid the
cumulative effect of those individuals. When the TNFa1b5
carrier rate was compared, it was significantly higher in
DR3-positive heterozygous T1D patients than in DR3-
positive heterozygous controls (66 out of 143 vs. 33 out
of 120; p = 0.0019; OR (95% CI) = 2.26 [1.3–3.93]). If we
do not want to discard the information corresponding to
the DR3-homozygous individuals, the comparison
should be made counting allelic rather than phenotypic
frequency and then normalising these counts by the total
number of DR3-positive haplotypes present in the DR3-
positive individuals (112/123 vs. 40/92, p = 0.001, OR =
2.09) (Table 1).
The results strongly suggest that the haplotype AH 18.2 is
over represented among DR3 haplotypes. To formally elu-
cidate whether this is the case, we observed that the allelic
frequency of DR3-TNFa1b5 (AH 18.2) is higher than that
of the DR3-positive abundant haplotype AH 8.1, which
carries TNFa2b3, (112/40 vs. 64/51, p = 0.002, OR (95%BMC Genomics 2005, 6:56 http://www.biomedcentral.com/1471-2164/6/56
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Table 1: Comparison of the TNFa1b5 allelic frequency in the DR3-positive T1D patient and control cohorts.
DR3-positive Individuals Total haplotypes DR3-positive haplotypes TNFa1b5 alleles TNFa2b3 alleles
T1D 189 378 235 112 64
Controls 126 252 132 40 51
Table 2: Frequency and number of DR3-positive haplotypes estimated by the Arlequin software.
T1D (2n = 596) Controls (2n = 1006)
Freq. Haplotypes Freq. Haplotypes
DR3-Total 0.39432 235 0.13120 132
I. DR3-a1b5 0.17276 103 0.03802 38
II. DR3-a2b3 0.10244 61 0.04866 49
III. DR3-other 0.11912 71 0.04452 45
I vs. II+III. OR = 1.93 (1.19–3.13); p = 0.004.
I vs. II. OR = 2.18 (1.24–3.83); p = 0.004.
I vs. III. OR = 1.72 (0.98–3.01); p = 0.043.
II vs. III. OR = 0.79 (0.45–1.39); p = 0.38.
Table 3: Comparison of the carrier rate of HLA class III genetic markers in the DR2-DQ6/DR3-DQ2/DR4-DQ8 negative diabetic and 
control cohorts.
Marker Allele T1D Controls OR p
D6S273 n = 29 n = 251
1 6 30 1.92 0.15
2 2 24 0.70 0.48
3 18 121 1.76 0.16
4 13 134 0.71 0.38
5 10 114 0.63 0.26
BAT-2 n = 29 n = 263
2 20 108 3.19 0.004
3 13 98 1.37 0.43
7 10 127 0.56 0.16
8 3 20 1.40 0.40
TNFab n = 29 n = 234
1,5 1 10 0.80 0.65
2,1 12 48 2.74 0.01
2,3 1 6 1.36 0.56
4,5 3 25 0.96 0.63
5,5 4 21 1.62 0.29
6,5 8 61 1.08 0.86
7,4 9 51 1.61 0.26
10,4 3 73 0.25 0.02
11,4 2 21 0.75 0.52
MICA n = 29 n = 233
4 8 45 1.59 0.30
5 6 62 0.72 0.49
5.1 5 74 0.45 0.11
6 22 141 2.05 0.11
9 12 78 1.40 0.40BMC Genomics 2005, 6:56 http://www.biomedcentral.com/1471-2164/6/56
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CI) = 2.23 [1.29–3.86]). Moreover, when the allele fre-
quencies of TNFa1b5 and TNFa2b3 were compared to the
total of TNFab alleles excluding the two aforementioned,
the AH18.2 showed significant difference (112/59 vs. 40/
41, p = 0.01, OR = 1.95) whereas TNFa2b3, AH8.1, did
not (64/59 vs. 51/41, p = 0.62, OR = 0.87). An alternative
approach would consist of applying an expectation-max-
imisation algorithm, as the one implemented by the Arle-
quin program to the sample genotypes. Table 2 shows the
DR3 three-loci haplotypes generated by this software
sorted into TNFa1b5 positives, TNFa2b3 positives and
other haplotypes. Again, TNFa1b5 is significantly differ-
ent from other DR3 haplotypes, while TNFa2b3 behaves
similarly to the rest.
In our Spanish sample this DR3-TNFa1b5 positive haplo-
type was present in a 33% T1D patients (98/298) vs. 7%
controls (37/504). The haplotypes ascertained by the Arle-
quin software yielded an AH 18.2 almost five times more
frequent in the Spanish patient than control cohorts
(Table 2). Moreover, almost one half (46%, 66/142) of
the DR3 heterozygous diabetic patients vs. one forth
(27%, 33/120) of the controls displayed a DR3-TNFa1b5
positive phenotype. On the contrary, in this subpopula-
tion the distribution of the other main DR3-positive hap-
lotype, AH 8.1, was similar between patients (43/142,
30%) and controls (47/120, 39%).
Therefore, these results confirmed the reported specific
diabetogenic role of the AH 18.2 in a Mediterranean pop-
ulation and are compatible with published observations
that established the presence of a second susceptibility
gene in the AH 18.2 [6,9] possibly located in either class
III or class I.
The second aim of this work was searching for additional
T1D susceptibility factors to the classical DQ2-DR3 and
DQ8-DR4 in the MHC region. Obviously, the subjects
studied should belong to DR3- and DR4-negative popula-
tions to eliminate the underlying genetic risk attributable
to these known risk factors and they were also stratified by
DR2, to avoid the effect of this allele negatively associated
with the disease. We tested the predisposition determined
by alleles of the five genetic markers in HLA class III
already studied (Table 3), and we also compared the dis-
tribution of the DQA1-DQB1 alleles (Table 4). Then, alle-
les TNFa10b4, DQA1*0501-DQB1*0301 and
DQA1*0103-DQB1*0603 for protection, and TNFa2b1,
BAT-2*2, DQA1*0101-DQB1*0501 and DQA1*0201-
DQB1*0202 for susceptibility, displayed statistical signif-
icant difference when T1D patients and healthy controls
were compared in the DR3, DR4 and DR2- negative pop-
ulation. These different alleles associated with T1D were
not mutually independent and linkage disequilibrium
was observed between TNFa2b1 and DQA1*0101-
DQB1*0501 (p = 9 × 10-5; D' = 0.34), BAT-2*2 and
DQA1*0201-DQB1*0202 (p = 4 × 10-7; D' = 0.36) and
weak LD between TNFa10b4 and DQA1*0103-
DQB1*0603 (p = 0.09; D' = 0.16). These results would
suggest the presence of extended haplotypes increasing
the risk to autoimmune diabetes in these conditions,
although the exact location of the susceptibility gene
remains undetermined. The allele 2 of microsatellite BAT-
2 within the haplotype DQA1*0201-DQB1*0202 is the
same present in the AH 18.2, and therefore a common
susceptibility region could potentially be shared by both
haplotypes. To test this possibility two adjacent markers
to BAT-2 were analysed, one telomeric, MN6S1879 and
other centromeric, N3-2-3. The MN6S1879*14 allele
present in the AH 18.2 is the same found in LD with BAT-
2*2 in the DR2-DQ6/DR3-DQ2/DR4-DQ8 negative
patients (p = 7 × 10-5; D' = 0.33). Curiously, provided the
extensive LD displayed by the AH 18.2, there are two dif-
ferent alleles (7 and 9) in the N3-2-3 marker corroborated
in our deficit IgA and celiac disease families, in
homozygous individuals and by Arlequin software. The
allele N3-2-3*7 did not show LD with BAT-2*2 in the tri-
ple negative population (p = 0.87, D' = 0.014), but N3-2-
3*9 (p = 0.052, D' = 0.26) showed a trend for association.
Although this latter allele seemed to mark higher risk than
N3-2-3*7, the difference did not reach statistical signifi-
cance. There was indirect evidence supporting the role of
the allele N3-2-3*9 in T1D susceptibility. In two DR3-
TNFa1b5 homozygous control individuals there were
Table 4: DQA1-DQB1 haplotypes in DR2-DQ6/DR3-DQ2/DR4-DQ8 negative T1D patients and controls.
Haplotype T1D (n = 29) Controls (n = 282) OR p
0101–0501 16 86 2.81 0.007
0102–0604 2 20 0.96 0.66
0103–0603 1 50 0.17 0.03
0201–0202 16 97 2.35 0.03
0201–0303 1 27 0.34 0.24
0401–0402 5 21 2.59 0.08
0501-0301 6 120 0.35 0.02BMC Genomics 2005, 6:56 http://www.biomedcentral.com/1471-2164/6/56
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three alleles N3-2-3*7 and one N3-2-3*9, while in nine
T1D patients, there were nine alleles each. Moreover, in
DR3-DQ2/DR4-DQ8 individuals carrying TNFa1b5, the
allele present in N3-2-3 is 9 (41 out of 83 vs. 0 from 14, p
= 0.0012) instead of 7 (25 out of 83 vs. 7 out of 12, p =
0.06, OR = 0.31). Of notice the different trend shown for
the allele 9 conferring susceptibility and for the allele 7
conferring protection. However, one must be cautious in
the interpretation of these data, as allele 9 is much more
haplospecific for AH 18.2 than allele 7, which appear in
several other haplotypes. Any ulterior analysis was pre-
vented given the lack of DR3-DQ2/DR4-DQ8 control sub-
jects displaying the AH 18.2.
Finally, we tried to ascertain the role as T1D susceptibility/
protection marker of the microsatellite located 4.9 Mb tel-
omeric of DQ in extended class I, D6S2223. In Northern
European countries allele D6S2223*3 was associated with
a reduction in risk independent of the class II effect [9,10]
and allele D6S2223*1 accounted for susceptibility to T1D
[6]. These associations were not observed in Sardinia [11].
In our DR3, DR4 and DR2-negative study group we did
not find any association (allele D6S2223*3 for protec-
tion: 28/29 in T1D patients vs. 223/234 in healthy con-
trols, OR = 1.38, p = 0.61; allele D6S2223*1 for
susceptibility: 0/29 vs. 2/234, p = 0.79). However, the lim-
ited number of patients after stratification decreases the
statistical power of detection for a positive association in
our population.
Discussion
Our observations support the distinctive effect on type 1
diabetes susceptibility of the AH 18.2 among all the other
DR3-positive haplotypes in the Spanish population. Both,
allelic and phenotypic frequencies showed the increased
risk conferred by the DR3-TNFa1b5 haplotype. Moreover,
the different behaviour in terms of T1D predisposition of
both DR3-positive main haplotypes, AH 8.1 and 18.2,
argues in favour of a second susceptibility locus besides
the standard class II molecules (DR and DQ) in the latter.
Previous studies reported the contribution to T1D suscep-
tibility of a second region in the MHC besides DQ-DR
genes. Among them, one concluded that this second
region extended between HLA-B and BAT-3 in the highest
risk DR3/DR4 genotype [12], while other mapped the crit-
ical region around the microsatellite D6S273 centromeric
to TNF [13]. TNF-α  has been identified as a diabetogenic
effector molecule synergistic with IFN-γ  in the induction
of β -cell apoptosis [14-16] and therefore, it was of interest
to consider the TNF region located in class III MHC as a
candidate susceptibility locus. Transfected cells contain-
ing BAT1 promoter fragments from the 8.1 AH exhibited
lower reporter activity compared to the 7.1 AH. Since the
7.1 and 8.1 AH are associated with resistance and suscep-
tibility to T1D respectively, the observed effects are
claimed to have significant implications for the pathogen-
esis of this disease [17]. We decided to study this region in
our population. Our findings of BAT-2*2, TNFa2b1 and
TNFa10b4 as genetic markers of the risk conferred by the
DQ-DR locus agrees with those previous reports in terms
of location. Most probably the etiological variant(s) will
be in linkage disequilibrium with the BAT-2*2 allele.
However, given the low recombination rate of the haplo-
type 18.2 (shown by the TNFa1b5 present in a DR3-nega-
tive context, see Table 3), and being BAT-2*2 a common
allele, this microsatellite could mark a different suscepti-
bility gene in the AH 18.2 and in other haplotypes.
Clearly, the analysis of genetic markers in class II and class
III provided an emerging pattern of susceptibility/protec-
tion haplotypes in addition to the classical DR3/DR4/
DR2 determinants. In this sense, one could speculate that
the traditional emphasis on class II alleles alone as
responsible for increasing the T1D risk could be an over-
simplification of a more complex reality where class III
markers remained in the background.
Population studies provide invaluable information help-
ing to map predisposition loci. A good example is the role
of D6S2223 as a marker of autoimmune diabetes in sev-
eral Nordic populations [9] which has been reproduced
neither in Sardinia [11] nor in Spain (present data).
A large number of studies from different populations
including the Spanish one [18] have indicated that com-
mon allelic variants at the class II HLA-DRB1, -DQA1 and
-DQB1 loci are associated with T1D. These MHC class II
molecules play an important role in the presentation of
peptide antigens after intracellular processing to CD4 T-
lymphocytes. The correlation between the relative T1D
predisposition of class II alleles and the structure of their
proteins has also been described [19]. However, the pres-
ence of HLA class II molecules alone does not by itself
cause disease. The HLA transgenic mice develop diabetes
when there is an islet "insult", even if the islet "insult" is,
itself, not sufficient to precipitate disease [17].
Conclusion
Our data prove that there are additional susceptibility/
protection factors besides DR3/DR4/DR2 in HLA in the
Spanish population and particular combinations of these
minor risk factors could have important effects on suscep-
tibility. The results of the present study provide evidence
of the importance of the whole HLA in T1D risk gradient
after stratification for the DR3, DR4 and DR2 determi-
nants. The accent placed on class II in the canonical DQ2-
DR3/DQ8-DR4 haplotypes is not necessarily extensive to
other associated haplotypes where susceptibility might
map to different MHC loci.BMC Genomics 2005, 6:56 http://www.biomedcentral.com/1471-2164/6/56
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Methods
302 T1D patients and 529 healthy unrelated controls,
both groups composed of Caucasian individuals from the
same Madrid area, were consecutively recruited after
informed consent obtained from the indexed subjects or
their parents when the patient was a child. The T1D
patients were diagnosed at two hospitals in Madrid and
the control subjects were collected among healthy blood
donors. The age at onset for the T1D patients (150 men
and 152 women) range 1–55 years old (median onset 15
years old). Diagnosis was based on patients' clinical fea-
tures and laboratory data according to the criteria of the
American Diabetes Association (ADA). All subjects were
insulin-dependent at the time of the study. Ab-positivity
was studied for GAD, IA-2, insulin and ICA. The protocol
followed the principles expressed in the Declaration of
Helsinki and was approved by the Hospital Ethics
Committee.
Both patients and controls were genotyped for HLA-
DQB1, DQA1 and DRB1 alleles [20] for 6 microsatellite
markers (D6S273, BAT-2, TNFa, TNFb, MICA and
D6S2223) as previously described [20-25]. Microsatellite
alleles were ascertained using an ABI Prism™ 310 auto-
matic sequencer (Applied Biosystems, Foster City, CA,
USA). Each sample included an internal size standard
(TAMRA 500, Applied Biosystems) to achieve a highly
consistent measure.
Allelic distribution and frequencies of the haplotypes
present in the control and diabetic cohorts were deter-
mined using a software for population genetics data anal-
ysis (Arlequin ver 2.000. Schneider S, Roessli D and
Excoffier L. University of Geneva, Switzerland). Haplo-
types were also corroborated by our previous findings in
families affected by other immune related diseases, by LD
studies in controls, and by the recent literature [6].
The frequencies of each marker allele in patients versus
controls were compared by a standard chi-square test
using a statistical software package (EPI-INFO v. 6.02;
Center for Disease Control & Prevention CDC, U.S.A.)
and a result was considered significant if p < 0.05. Statis-
tics are performed upon the individuals with available
data in the markers under comparison; therefore the final
number could differ among different analyses. As our
working hypothesis was to verify in the Spanish popula-
tion the presumed special association with T1D of the
characteristic alleles of the AH 18.2, there was no need for
Bonferroni corrections in these initial comparisons.
Abbreviations
T1D type 1 diabetes
MHC Major Histocompatibility Complex
HLA human leukocyte antigen
AH ancestral haplotype
LD linkage disequilibrium
TNF tumor necrosis factor
OR odds ratio
LTA lymphotoxin alpha.
Freq. frequency
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